Lundbeck Secures FDA Orphan Drug Designation For Asedebart In Cushing's Syndrome

Lundbeck received U.S. FDA Orphan Drug Designation for investigational antibody Asedebart (Lu AG13909) in endogenous Cushing's syndrome. The designation supports development in a rare disease indication and may provide regulatory and commercial incentives, though the therapy remains investigational.